Verastem, Inc. VSTM, focused on discovering and developing
drugs to treat cancer by the targeted killing of cancer stem cells,
today announced the initiation of a Phase 1 trial of defactinib
(VS-6063), a potent inhibitor of focal adhesion kinase (FAK), in
Japanese patients with advanced solid tumors. FAK is a pathway critical
for the growth and survival of cancer stem cells and the study marks the
launch of Verastem's development efforts in Japan.
The Phase 1 open-label, dose-escalation study, which will be conducted
at Kinki University in Osaka, is designed to assess the safety,
pharmacokinetics and pharmacodynamics of single agent defactinib. The
study will enroll 12-18 patients. Pending a successful outcome to the
Phase
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in